The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIX.i

Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

Publications

Yun H, Xie F, Beyl RN, Chen L, Lewis JD, Saag KG, Curtis JR

Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.

Arthritis care & research 2017 10;69;1526-1534 — 2017 10 — 1526-1534

Cartin-Ceba R, Golbin JM, Keogh KA, Peikert T, Sánchez-Menéndez M, Ytterberg SR, Fervenza FC, Specks U

Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.

Arthritis and rheumatism 2012 Nov;64;3770-8 — 2012 Nov — 3770-8

Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Schellekens H, Leufkens HG, Egberts AC

Safety-related regulatory actions for biologicals approved in the United States and the European Union.

JAMA 2008 Oct 22;300;1887-96 — 2008 Oct 22 — 1887-96

Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999 Mar;17;791-5 — 1999 Mar — 791-5